United States Patent 9,186,344: Claim Scope, Triheptanoin Patent Landscape, Exclusivity and Generic Risk

U.S. Patent No. 9,186,344 protects compositions containing a seven-carbon fatty-acid source, including triheptanoin, that meet tightly defined acid-value and hydroxyl-value specifications. Its claims also cover dosage amounts, caloric contribution, administration routes, dosage-unit sizes and treatment duration.

The patent is most relevant to pharmaceutical, nutritional and medical-food products containing high-purity triheptanoin or related heptanoate materials. It does not broadly cover every triheptanoin product. A potentially infringing product must satisfy the claim 1 composition and quality limitations, together with any additional limitations in an asserted dependent claim.

What does U.S. Patent 9,186,344 protect?

The independent claim protects a composition comprising:

A seven-carbon fatty-acid source;
A source selected from n-heptanoic acid, a triglyceride comprising n-heptanoic acid, or triheptanoin;
An acid value of no more than 0.1 mg KOH/g;
A hydroxyl value of no more than 2.8 mg KOH/g; and
Formulation for parenteral, oral or enteral administration.

The patent therefore combines chemical identity, compositional purity and intended administration route. The acid-value and hydroxyl-value limitations are central. A triheptanoin formulation outside either threshold may avoid literal infringement of claim 1 even if it contains the same active fatty-acid source.

The use of “comprising” makes the claim open-ended. A product may contain additional oils, excipients, stabilizers, vitamins, minerals or other nutritional components and still fall within the claim if it contains the required seven-carbon fatty-acid source and satisfies the numerical specifications.

How should claim 1 be construed?

Claim 1 is a composition claim, not a method-of-treatment claim. It does not expressly require administration to a patient, a particular disease, a particular patient population or a particular therapeutic result.

The phrase “formulated for parenteral, oral, or enteral administration” is broader than an express limitation requiring actual administration. A product marketed as an oral nutritional or pharmaceutical formulation may satisfy this limitation even if a particular patient never receives it.

The principal claim elements are:

Claim element	Scope and infringement significance
“Composition comprising”	Open-ended; permits additional ingredients
Seven-carbon fatty-acid source	Covers specified C7 fatty-acid materials and triglyceride sources
n-Heptanoic acid	Free C7 fatty acid
Triglyceride comprising n-heptanoic acid	Potentially covers mixed triglycerides containing heptanoate chains
Triheptanoin	Triglyceride containing three heptanoic-acid residues
Acid value ≤0.1 mg KOH/g	Tight limit on free-acid or acid-generating impurities
Hydroxyl value ≤2.8 mg KOH/g	Tight limit on hydroxyl-containing impurities or residual materials
Parenteral, oral or enteral formulation	Covers multiple delivery pathways

The claim does not state a minimum triheptanoin concentration, a specific excipient system, a particular container, a disease indication or a manufacturing process.

What do claims 2 through 26 add?

The dependent claims divide into five principal groups.

Chemical-source claims

Claims 2 and 3 identify specific C7 materials:

Claim 2 covers heptanoic acid or a triglyceride thereof.
Claim 3 identifies heptanoin, heptanoate or triheptanoin.

These claims may provide narrower positions around commercial forms of the active ingredient. Claim 3 also raises a drafting and construction issue because it introduces “heptanoin” and “heptanoate” terminology not stated in the same form in claim 1. As a dependent claim, it must retain all limitations of claim 1 while adding its own limitation. The inconsistency could create claim-construction or validity arguments, but it does not automatically eliminate enforceability.

Dose-per-body-weight claims

Claims 4 through 7 cover daily amounts:

Claims	Dose range
4	1 to 4 g/kg/day
5	1 to 3 g/kg/day
6	1 to 2 g/kg/day
7	0.1 to 2 g/kg/day

Claims 22 through 24 add duration requirements of at least seven or fourteen days. Claim 26 separates infant and adult dosing, covering 1 to 4 g/kg/day for infants and 0.1 to 2 g/kg/day for adults.

These claims are narrower than claim 1 and may be more difficult to assert against a product sold without dosing instructions. They become more relevant where labeling, prescribing information, clinical protocols or promotional materials recommend the claimed ranges.

Dosage-unit claims

Claims 8 through 10 cover dosage units containing at least 15 grams, 15 to 75 grams, or 75 grams of the C7 source.

A package, pouch, bottle or unit-dose container may raise infringement issues if the claimed amount is present per dosage unit. The analysis depends on how “dosage unit” is construed and whether the amount refers to the active C7 source, total formulation weight or another measurable quantity. The claim language indicates that the amount is the amount of the seven-carbon fatty-acid source, not the total product mass.

Caloric-contribution claims

Claims 11 through 15 cover products supplying:

15% to 40% of daily dietary calories;
20% to 35%;
25% to 35%;
30%; or
25%.

These limitations connect the patent to complete or supplemental nutrition products rather than only to pharmaceutical active-ingredient formulations. A commercial product could satisfy multiple overlapping claims depending on its recommended daily dose and caloric labeling.

Product and route claims

Claims 16 through 21 cover:

Nutritional supplements;
Dietary formulations;
Pharmaceutical compositions;
Parenteral administration;
Enteral administration; and
Oral administration.

These claims do not require a new chemical entity. They cover product categories and administration routes layered onto the claim 1 composition.

How strong is the patent estate based on the issued claims?

The patent has meaningful commercial breadth but several potential enforcement constraints.

Strengths

First, claim 1 covers the composition itself. A composition claim can be asserted against manufacture, importation, sale or offer for sale without proving that a particular patient used the product in a claimed manner.

Second, the claim captures quality characteristics that may correspond to a commercial-grade triheptanoin product. If a manufacturer necessarily produces material with acid and hydroxyl values below the claimed limits, those characteristics can support infringement.

Third, the claims cover oral, enteral and parenteral products. This prevents a design-around based solely on changing the delivery route.

Fourth, claims 8 through 15 align with commercial packaging and nutrition labeling. A product sold in 15-gram or larger units and promoted as a substantial calorie source may implicate several dependent claims.

Weaknesses and design-around opportunities

The numerical limits create testing and proof requirements. The patent owner would need reliable analytical evidence showing that the accused composition has an acid value of no more than 0.1 mg KOH/g and a hydroxyl value of no more than 2.8 mg KOH/g.

The patent does not expressly claim every C7 lipid. A formulation containing a different odd-chain fatty acid, such as a five-carbon or nine-carbon source, may fall outside the literal scope. A product based on a seven-carbon compound that is not heptanoic acid, heptanoate, heptanoin or a qualifying triglyceride may also present a noninfringement position.

The dose and caloric claims depend on labeling and use. A manufacturer that sells a composition without a recommended dose in the claimed ranges may reduce risk under those claims, although claim 1 remains independent of dose.

What is the likely relationship to triheptanoin products such as Dojolvi?

Triheptanoin is the active ingredient in Dojolvi, marketed by Ultragenyx Pharmaceutical Inc. for patients with long-chain fatty-acid oxidation disorders. The FDA approved Dojolvi in 2020 as a source of calories and fatty acids for patients with long-chain fatty-acid oxidation disorders [2].

Dojolvi is an oral liquid formulation. Its label describes dosing based on a percentage of total daily caloric intake and recommends administration with food or drink [2]. Those characteristics are commercially relevant to claims 11 through 15 and claims 16, 17 and 21.

The FDA label does not by itself establish infringement. Infringement requires comparison of the marketed formulation, analytical specifications, product labeling and applicable claim construction against the issued claims.

What is the Orange Book status of U.S. Patent 9,186,344?

A patent number appearing in the U.S. patent system does not establish that the patent is listed in the FDA Orange Book. Orange Book listing depends on submission by the NDA holder and FDA acceptance under the applicable listing rules.

For a drug product such as Dojolvi, relevant Orange Book categories may include composition patents, formulation patents and method-of-use patents. A composition patent can create an FDA patent-certification issue if it is properly listed against the NDA. The listing status must be evaluated separately from patent validity, enforceability and expiration.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed. A Paragraph III certification would accept that the patent has not expired. The patent text supplied here does not establish whether U.S. Patent 9,186,344 is currently listed, delisted or associated with a specific NDA.

When does U.S. Patent 9,186,344 lose exclusivity?

The patent issued on November 17, 2015. Its expiration date cannot be established from the claims alone because U.S. patent term depends on the effective nonprovisional filing date, priority chain, patent-term adjustment, terminal disclaimers and any applicable patent-term extension.

For a typical utility patent, the statutory term is generally 20 years from the earliest effective nonprovisional U.S. filing date, subject to adjustment and statutory exceptions [3]. The issue date is therefore not the expiration date.

The patent’s practical exclusivity also depends on:

Whether the patent is listed in the Orange Book;
Whether the patent has been challenged;
Whether a court finds the claims valid and infringed;
Whether later patents cover the same commercial product;
Whether regulatory exclusivity remains available; and
Whether a settlement agreement restricts generic launch.

What Paragraph IV and generic-entry risks exist?

A generic or follow-on applicant could attack the patent through several theories.

Invalidity theories

Potential arguments include:

Lack of anticipation or obviousness based on earlier triheptanoin and odd-chain fatty-acid formulations;
Indefiniteness of “suitable for” dosage and calorie limitations;
Lack of written description for the full range of fatty-acid sources;
Enablement concerns across parenteral, oral and enteral formulations;
Ambiguity in the relationship between claims 1, 2 and 3;
Inadequate support for the acid-value and hydroxyl-value thresholds; and
Obviousness of selecting low-impurity triheptanoin for pharmaceutical use.

Noninfringement theories

A competing product could argue that it:

Has an acid value above 0.1 mg KOH/g;
Has a hydroxyl value above 2.8 mg KOH/g;
Uses a nonqualifying C7 source;
Is not formulated for one of the claimed administration routes;
Does not contain the claimed amount per dosage unit; or
Does not carry the dose or caloric instructions required by a dependent claim.

A generic applicant would also need to assess other active patents covering triheptanoin composition, formulation, manufacturing, stability, labeling or treatment methods. Avoiding U.S. Patent 9,186,344 alone would not necessarily create a marketable launch path.

Are biosimilar risks relevant?

Biosimilar risk is not the primary pathway because triheptanoin is a chemically defined lipid, not a biologic. A competing product would more likely use an abbreviated new drug application, a 505(b)(2) application or a full NDA, depending on formulation, labeling and reference-product reliance.

The main regulatory barriers are pharmaceutical equivalence, impurity control, stability, product quality, bioavailability and clinical bridging. A formulation materially different from Dojolvi could face 505(b)(2) requirements rather than a straightforward generic route.

What patent litigation and licensing issues matter?

The commercial history of triheptanoin includes development and licensing activity involving academic and biotechnology organizations before commercialization by Ultragenyx. Licensing arrangements can determine who owns, controls or enforces individual patent families. They do not change the issued claim scope.

For transaction diligence, parties should separate:

Ownership of U.S. Patent 9,186,344;
Exclusive and nonexclusive field rights;
Sublicense rights;
Royalty obligations;
Patent-prosecution control;
Enforcement rights;
Settlement restrictions; and
Rights to improvements and manufacturing know-how.

The supplied information does not establish a litigation judgment, Paragraph IV settlement or license restriction specific to Patent 9,186,344.

How does this patent compare with manufacturing and formulation patents?

U.S. Patent 9,186,344 is principally a composition and use-context patent. It does not, based on the supplied claims, expressly claim:

A specific esterification process;
A purification sequence;
A catalyst;
A reactor configuration;
A packaging system;
A particular emulsifier;
A stability-improvement method; or
A manufacturing batch process.

Those areas may be protected by separate patent families. Manufacturing patents can remain commercially significant even where a composition patent expires, particularly if the patented process is necessary to achieve the acid-value and hydroxyl-value specifications.

Key Takeaways

U.S. Patent 9,186,344 centers on high-purity seven-carbon fatty-acid compositions, especially triheptanoin.
Claim 1 requires both an acid value of no more than 0.1 mg KOH/g and a hydroxyl value of no more than 2.8 mg KOH/g.
The patent covers oral, enteral and parenteral formulations.
Dependent claims add dose, duration, dosage-unit and caloric-contribution limitations.
Dojolvi’s oral triheptanoin product is commercially aligned with several dependent-claim categories, but the FDA label alone does not prove infringement.
The patent’s expiration date cannot be calculated from the claims or issue date alone.
Generic risk depends on Orange Book listing, later patents, claim validity, product testing and any Paragraph IV settlement.
Biosimilar analysis is generally inapposite because triheptanoin is a chemically defined lipid rather than a biologic.
Manufacturing, purification and formulation patents may create additional barriers after this patent expires.

FAQs

Does Patent 9,186,344 cover all triheptanoin products?

No. The product must also satisfy the acid-value and hydroxyl-value limitations and be formulated for parenteral, oral or enteral administration.

Can a product avoid infringement by using a different dosage?

Possibly for claims 4 through 7 and 22 through 26, but dosage does not avoid claim 1, which has no express dose limitation.

Do the claims cover mixed triglycerides containing heptanoic acid?

Claim 1 expressly includes a triglyceride comprising n-heptanoic acid. The exact scope depends on the meaning of “comprising” and the composition of the triglyceride.

Is U.S. Patent 9,186,344 a method-of-treatment patent?

The supplied claims are composition claims and composition-linked dosage claims. They do not expressly recite treating a named disease.

Can a competitor launch after avoiding this patent?

Not necessarily. A launch requires clearance of the complete patent estate, FDA requirements, Orange Book certifications, manufacturing rights, formulation patents and any applicable regulatory exclusivity.

References

U.S. Patent No. 9,186,344. (2015). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2020). Dojolvi (triheptanoin) prescribing information.
United States Code, 35 U.S.C. § 154. Patent term.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2573054	⤷ Start Trial
Canada	2784420	⤷ Start Trial
Canada	2784585	⤷ Start Trial
European Patent Office	1773317	⤷ Start Trial
European Patent Office	3300727	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,186,344

Summary for Patent: 9,186,344